Allianz Asset Management GmbH increased its stake in Revance Therapeutics Inc (NASDAQ:RVNC) by 16.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 79,437 shares of the biopharmaceutical company’s stock after buying an additional 11,271 shares during the quarter. Allianz Asset Management GmbH’s holdings in Revance Therapeutics were worth $2,447,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Cowen Inc. acquired a new stake in Revance Therapeutics in the 4th quarter valued at about $225,000. Teacher Retirement System of Texas acquired a new stake in Revance Therapeutics in the 4th quarter valued at about $255,000. Quinn Opportunity Partners LLC acquired a new stake in Revance Therapeutics in the 4th quarter valued at about $325,000. Two Sigma Advisers LP acquired a new stake in Revance Therapeutics in the 4th quarter valued at about $343,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Revance Therapeutics in the 4th quarter valued at about $392,000. 92.97% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on the stock. Mizuho cut their price target on shares of Revance Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a report on Friday, April 20th. BidaskClub raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 20th. Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Goldman Sachs Group assumed coverage on shares of Revance Therapeutics in a report on Monday, March 5th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 29th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Revance Therapeutics presently has a consensus rating of “Buy” and an average price target of $45.91.
RVNC stock opened at $28.65 on Thursday. Revance Therapeutics Inc has a one year low of $22.05 and a one year high of $37.45. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -7.14 and a beta of 1.33.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.26). Revance Therapeutics had a negative net margin of 33,807.37% and a negative return on equity of 63.68%. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.15 million. equities research analysts predict that Revance Therapeutics Inc will post -3.87 EPS for the current fiscal year.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.